In Apoe+ mice with STZ-induced diabetes, genetic deletion of Nox1 or pharmacological inhibition using GKT137831 (setanaxib, a dual NOX1/NOX4 inhibitor) significantly reduced atherosclerotic burden [18], as evidenced by decreased plaque area and improved plaque morphology [19]. Here, NOX1 is linked to diabetes mellitus.